All News

mitochondrial,DNA

Mitochondria as Master Regulators of Inflammation

Jack Cush, MD

Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.

Read Article
cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Jack Cush, MD

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

Jack Cush, MD

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article
Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa

Links:

Dr. John Cush RheumNow ( View Tweet)
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/QokXF6klEv https://t.co/YqFgAqt4ku

Links:

Dr. John Cush RheumNow ( View Tweet)
🌏 Today is World Sjögren's Day!🌍 🩺 Sjögren's is not Just Dry eyes👁️ and Dry Mouth👅👄 - there's much more to it There's still a lot about this 'invisible' #Autoimmune Disorder, we don't know Clinical Features and Pathogenesis #LetstalkaboutSjögrens #MedTwitter #RheumTwitter https://t.co/t9toed8MG7
EnvisionRheumat ERheumat ( View Tweet)
#EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial cc: @Yuz6Yusof https://t.co/1tDBNzTuwQ
Dr. John Cush RheumNow ( View Tweet)
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx

Links:

Dr. John Cush RheumNow ( View Tweet)
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Richard Conway RichardPAConway ( View Tweet)
New Tool! STAR (#Sjogren’s Tool for Assessing Response) was developed to assess treatment response in primary Sjogren’s and will be validated on 3 datasets #EULAR2022 @rheumnow OP0286 https://t.co/9tgVSWGxEc
TheDaoIndex KDAO2011 ( View Tweet)
Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2

Links:

Richard Conway RichardPAConway ( View Tweet)
#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ClinicalPearl Autoantibodies in #Sjogren’s Syndrome include CCP and anticentromere - think of overlaps with #rheumatoid arthritis or lcSSc limited cutaneous systemic sclerosis #scleroderma #CCR22 #CCR2022 ⁦@RheumNow⁩ https://t.co/vrdbv640B5
Janet Pope Janetbirdope ( View Tweet)
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/SLn2qs8En4 https://t.co/nMOUm2C9It

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×